JP7408557B2 - イミダゾジアゼピンジオン及びその使用方法 - Google Patents

イミダゾジアゼピンジオン及びその使用方法 Download PDF

Info

Publication number
JP7408557B2
JP7408557B2 JP2020543957A JP2020543957A JP7408557B2 JP 7408557 B2 JP7408557 B2 JP 7408557B2 JP 2020543957 A JP2020543957 A JP 2020543957A JP 2020543957 A JP2020543957 A JP 2020543957A JP 7408557 B2 JP7408557 B2 JP 7408557B2
Authority
JP
Japan
Prior art keywords
methyl
compound according
chlorophenyl
compound
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020543957A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516225A5 (https=
JP2021516225A (ja
Inventor
ダニエルズ，マシュー，エイチ．
ユー，マオリン
ハーマンジ，ジーン－クリストフ，ピー．
ティビット，トマス，ティー．
レデボアー，マーク，ダブリュー．
キャッスル，ニール，エー．
マロジェシク，ゴラン
Original Assignee
ゴールドフィンチ バイオ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゴールドフィンチ バイオ，インク． filed Critical ゴールドフィンチ バイオ，インク．
Publication of JP2021516225A publication Critical patent/JP2021516225A/ja
Publication of JP2021516225A5 publication Critical patent/JP2021516225A5/ja
Priority to JP2023214175A priority Critical patent/JP7809096B2/ja
Application granted granted Critical
Publication of JP7408557B2 publication Critical patent/JP7408557B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
JP2020543957A 2018-03-05 2019-03-05 イミダゾジアゼピンジオン及びその使用方法 Active JP7408557B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023214175A JP7809096B2 (ja) 2018-03-05 2023-12-19 イミダゾジアゼピンジオン及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862638448P 2018-03-05 2018-03-05
US62/638,448 2018-03-05
PCT/US2019/020732 WO2019173327A1 (en) 2018-03-05 2019-03-05 Imidazodiazepinediones and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023214175A Division JP7809096B2 (ja) 2018-03-05 2023-12-19 イミダゾジアゼピンジオン及びその使用方法

Publications (3)

Publication Number Publication Date
JP2021516225A JP2021516225A (ja) 2021-07-01
JP2021516225A5 JP2021516225A5 (https=) 2022-03-14
JP7408557B2 true JP7408557B2 (ja) 2024-01-05

Family

ID=67847465

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543957A Active JP7408557B2 (ja) 2018-03-05 2019-03-05 イミダゾジアゼピンジオン及びその使用方法
JP2023214175A Active JP7809096B2 (ja) 2018-03-05 2023-12-19 イミダゾジアゼピンジオン及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023214175A Active JP7809096B2 (ja) 2018-03-05 2023-12-19 イミダゾジアゼピンジオン及びその使用方法

Country Status (7)

Country Link
US (2) US11623930B2 (https=)
EP (1) EP3761989A4 (https=)
JP (2) JP7408557B2 (https=)
CN (2) CN118908961A (https=)
AU (2) AU2019231208B2 (https=)
CA (1) CA3093084A1 (https=)
WO (1) WO2019173327A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093084A1 (en) 2018-03-05 2019-09-12 Goldfinch Bio, Inc. Imidazodiazepinediones and methods of use thereof
JP2022551580A (ja) * 2019-10-04 2022-12-12 ゴールドフィンチ バイオ，インク． 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置
CN115927202A (zh) * 2023-01-10 2023-04-07 北京爱思益普生物科技股份有限公司 一种trpc5突变细胞株及其构建方法和应用
WO2024153028A1 (zh) * 2023-01-20 2024-07-25 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020460A1 (en) * 1993-03-11 1994-09-15 Smithkline Beecham Corporation Chemical compounds
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
TW201444844A (zh) * 2013-03-14 2014-12-01 Hydra Biosciences Inc 經取代之黃嘌呤及使用其之方法
CN107082782B (zh) 2013-03-15 2020-03-20 海德拉生物科学有限责任公司 取代的黄嘌呤及其使用方法
JP6667092B2 (ja) 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体
DK3652176T3 (da) 2017-07-11 2022-01-17 Boehringer Ingelheim Int Substituerede xanthinderivater
CA3093084A1 (en) 2018-03-05 2019-09-12 Goldfinch Bio, Inc. Imidazodiazepinediones and methods of use thereof
EP3917940A1 (en) * 2019-01-30 2021-12-08 Rothamsted Research Ltd Cylodimer of dehydrosalicortin and derivatives thereof isolated from plant of the genus salix for use in cancer therapy

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Bridson, Peter K. et al.，Cyclic homologs of xanthines. I. Imidazo[4,5-e][1,4]diazepine-5,8-diones，Journal of Heterocyclic Chemistry，1988年，25(4),，1179-82
Correa, Arkaitz et al.，An efficient, PIFA-mediated approach to benzo-, naphtho-, and heterocycle-fused pyrrolo[2,1-c][1,4]diazepines. An advantageous access to the antitumor antibiotic DC-81，Journal of Organic Chemistry ，2005年，70(6),，2256-2264
Daly, John W. et al.，Imidazodiazepinediones: a new class of adenosine receptor antagonists，Journal of Medicinal Chemistry，1990年，33(10),，2818-21
Ivanov, E. I.，Novel synthesis and reactions of 1,4,7-trimethyl-4,5,7,8-tetrahydro-6H-imidazo[4,5-e][1,4]diazepine-5,8-dione - a cyclic caffeine analog，Chemistry of Heterocyclic Compounds (New York)(Translation of Khimiya Geterotsiklicheskikh Soedinenii) ，1998年，34(6),，719-722
Malcor, Jean-Daniel et al.，Synthesis and reactivity of pyrrolo[3,2-d][1,3]oxazine-2,4-dione. Access to new pyrrolo[3,2-e][1,4]diazepine-2,5-diones，Tetrahedron，2014年，70(31),，4631-4639
Reddy, Nalla Ram et al.，A new entry to pyrazolo[4,3-e][1,4]diazepines. Facile synthesis of pyrazolo [4,3-e][1,4]diazepin-5,8-diones, 5,6,8-triones and pyrazolo[4,3-e]pyrrolo-[1,2-a][1,4]diazepin-5,10-diones，Journal of Heterocyclic Chemistry ，2005年，42(4),，675-678
REGISTRY(STN)[online]，28 Feb 2002[検索日 2023.1.23]CAS登録番号 396723-38-9

Also Published As

Publication number Publication date
JP2024037971A (ja) 2024-03-19
US20210087200A1 (en) 2021-03-25
US20230365575A1 (en) 2023-11-16
AU2019231208B2 (en) 2025-01-23
EP3761989A4 (en) 2021-11-24
US11623930B2 (en) 2023-04-11
JP7809096B2 (ja) 2026-01-30
AU2025202716A1 (en) 2025-05-08
CN112351781A (zh) 2021-02-09
US12466834B2 (en) 2025-11-11
JP2021516225A (ja) 2021-07-01
WO2019173327A1 (en) 2019-09-12
AU2019231208A1 (en) 2020-09-17
CN118908961A (zh) 2024-11-08
CN112351781B (zh) 2024-07-02
CA3093084A1 (en) 2019-09-12
EP3761989A1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
JP7809096B2 (ja) イミダゾジアゼピンジオン及びその使用方法
JP7474243B2 (ja) ピリダジノン及びその使用法
JP7082446B2 (ja) スルホキシイミングリコシダーゼ阻害剤
US20230374143A1 (en) A sortilin antagonist for use in the prevention or treatment of hearing loss
JP2023546742A (ja) Ｌｐａ受容体活性に付随する症状を治療するための化合物および組成物
WO2019028308A1 (en) BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES AND METHODS OF USE
EA048445B1 (ru) Пиридазиноны и способы их применения
HK40115225A (en) Pyridazinones and methods of use thereof
HK40056020A (en) Pyridazinones and methods of use thereof
HK40056020B (en) Pyridazinones and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220304

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230110

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230110

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230731

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231220

R150 Certificate of patent or registration of utility model

Ref document number: 7408557

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02